←
Samuel A. Sprowls, PhD378 posts
Samuel A. Sprowls, PhD avatar

Samuel A. Sprowls, PhD

@SamuelSprowls

Assistant Professor @DuquensePharm. Expertise in blood-brain barrier, pharmacokinetics, and brain tumor modeling. Tweets are my own.

◷ Joined April 2022▧ 47 Photos and videos
Duquesne Pharmacy avatar
⟳ Samuel A. Sprowls, PhD retweeted
Duquesne Pharmacy@DuquesnePharm·24 Mar 2025

We are excited to announce that our School of Pharmacy attained the highest residency match rate in Pennsylvania! This is a testament to #DuqPharm helping our students become empowered pharmacists. Over 30% of students will be entering their PGY1 residency after Phase 1!

Post attachment
Duquesne Pharmacy avatar
⟳ Samuel A. Sprowls, PhD retweeted
Duquesne Pharmacy@DuquesnePharm·24 Feb 2025

We would like to thank all our prospective students and families for attending Admitted Students Day yesterday! It was a successful event filled with student panels, lab demonstrations, and much more! Thank you for seeing what our #DuqPharm life is all about!

Post attachmentPost attachmentPost attachmentPost attachment
Olivier George avatar
⟳ Samuel A. Sprowls, PhD retweeted
Olivier George@brainaddiction·19 Feb 2025

It's clear that many do not understand what @NIH-funded research does to improve health. It's time to revive a study published 10 years ago that provides incredible information about this. link in the comment Every single new drug approved by the FDA from 2010–2016 was built on NIH-funded research—that’s all 210 drugs. But what the public sees is just the tip of the iceberg. Pharma takes credit for the final product, but beneath each drug developed, there are ~20 years of basic research, and 90% of the cost is from basic research funded by the NIH, which discovers drug targets, understands disease mechanisms, and creates life-saving treatments. Figuring out how cancer evades the immune system, how addiction rewires the brain, and how heart disease develops is the role of the NIH, creating the foundation for the breakthrough drugs that come 20 years later, and the NIH does all that with only 0.8% of the US budget. Without NIH, there would be no cancer immunotherapy, no anti-overdose medication, no anti-heart attack or stroke medication, no cutting-edge treatments. If NIH funding is cut, the iceberg will melt. That means fewer cures, more suffering, and more lives lost. The science beneath the surface keeps us afloat. Invest in NIH. Invest in life

Post attachment
Sylvester Comprehensive Cancer Center avatar
⟳ Samuel A. Sprowls, PhD retweeted
Sylvester Comprehensive Cancer Center@SylvesterCancer·3 Feb 2025

Dr. Defne Bayik (@d_bayik), member of the Sylvester Brain Tumor Institute, studies glioblastomas with the goal of developing new treatments for patients. We recently chatted to learn more about her work at Sylvester and @umiamimedicine. 💬 loom.ly/S1KqixE

Duquesne Pharmacy avatar
⟳ Samuel A. Sprowls, PhD retweeted
Duquesne Pharmacy@DuquesnePharm·28 Jan 2025

What does being a member of the 100th School of Pharmacy class mean? Hear from Henry DiPaolo, a 2025 Pharm.D. graduate, on what this means to him. Register for our Centennial Celebration: shorturl.at/tfh2P #DuqPharm

0:31
Duquesne University avatar
⟳ Samuel A. Sprowls, PhD retweeted
Duquesne University@duqedu·22 Jan 2025

Room With a View 👀 Campus and Pittsburgh are looking beautiful on this cold winter morning.

Post attachment
Devika S Manickam (she/her) avatar
⟳ Samuel A. Sprowls, PhD retweeted
Devika S Manickam (she/her)@manickam_lab·16 Jan 2025

This R01 award is a collective effort between our lab and phenomenal team of collaborators @LD_McCullough # Venu Venna @UTHealthHouston @SShivaLab @SrutiShiva @PittDeptofMed #Stacy Wendell #Bill Banks @UW. Much gratitude to all!

Congratulations to #DuqPharm professor Devika Manickam, Ph.D. on receiving a grant from the National Institutes of Neurological Disorders & Stroke supporting development of extracellular vesicles that deliver mitochondria to help protect the blood-brain barrier after a stroke.

Post attachment
Anthony R. Sloan, Ph.D. avatar
⟳ Samuel A. Sprowls, PhD retweeted
Anthony R. Sloan, Ph.D.@AnthonyrSloan·10 Jan 2025

Checkout our pre-print where we conducted a large scale clinical analysis looking at VTE rates in GBM. Excited to share mechanistic work in the near future showing how thrombosis drives GBM progression. medrxiv.org/content/10.1101/…